Introduction
On 21 October 2026, the UK Government confirmed the indefinite recognition of CE-marked medical devices and in vitro diagnostic medical devices (IVDs) in Great Britain. This decision provides greater certainty for manufacturers that rely on the European regulatory framework to access the GB market. The announcement will ensure continued access to products already approved under the European Union regulatory framework.
The government conducted public consultation between February and April 2026 and received more than 1,000 responses from patients, healthcare organizations, manufacturers, and industry stakeholders. Through this announcement it provides long-term regulatory certainty and reinforces the UK's commitment to maintaining patient access to safe and effective medical technologies.
Scope of the Decision
The indefinite recognition policy applies to:
After this announcement, manufacturers will not be required to seek an additional approval route because the device already holds valid CE certification. The policy will operate alongside the UKCA marking pathway, which is the domestic route for placing medical devices on the Great Britain market.
Importance of the Announcement
1. Provides Long-Term Regulatory Certainty
Since the UK's departure from the European Union, manufacturers have closely monitored changes to market access requirements. The decision to indefinitely recognize CE-marked devices remove uncertainty and provides a stable regulatory environment for businesses planning product launches and long-term investments.
2. Supports Continued Patient Access
More than 90% of medical devices currently registered in Great Britain carry CE marking. Continued recognition will help ensure uninterrupted availability of critical healthcare technologies such as diagnostic equipment, surgical instruments, implantable devices and digital health solutions.
3. Strengthens Supply Chain Resilience
Avoiding duplicate regulatory approvals reduces administrative barriers and minimizes the risk of supply disruptions. This is particularly important for healthcare providers and the NHS, which rely on consistent access to a broad range of medical technologies.
4. Aligns with MHRA's Future Regulatory Vision
The announcement supports the MHRA's strategy of increasing reliance on trusted international regulatory authorities while strengthening domestic oversight through enhanced post-market surveillance and vigilance systems.
Benefits for Manufacturers and Patients
Benefits for Manufacturers
Reduced Regulatory Burden
Manufacturers can continue using existing EU conformity assessments without facing additional approval requirements for CE-marked products entering the Great Britain market.
Lower Compliance Costs
The elimination of duplicate approval pathways reduces regulatory expenses, resource commitments, and administrative complexity.
Greater Market Predictability
A clear and stable framework enables companies to plan investments, market expansion activities, and regulatory strategies with greater confidence.
Faster Access to the UK Market
Manufacturers can maintain efficient market entry pathways, helping innovative products reach healthcare providers and patients more quickly.
Support for Innovation
The UK's planned modernization of its regulatory framework is expected to facilitate the introduction of emerging technologies, including software-based medical devices and AI-enabled healthcare solutions.
Benefits for Patients
Continued Access to Medical Devices
Patients will benefit from access to a wide range of medical devices and diagnostics already approved by European regulatory systems.
Reduced Risk of Shortages
The policy helps prevent market withdrawal of CE-marked products which supports continuity of supply of medical devices and emerging technologies.
Faster Access to New Technologies
Streamlined market access can fast-track the availability of innovative treatments, diagnostic tools, and digital health solutions.
Maintained Safety Oversight
The MHRA will continue monitoring device safety through vigilance reporting requirements, post-market surveillance and mechanisms such as the Yellow Card Scheme, ensuring patient safety remains a priority.
Timeline of Key Developments
| Date | Milestone |
|---|---|
| 16 February 2026 | MHRA launched a public consultation on indefinite recognition of CE-marked medical devices. |
| 10 April 2026 | Consultation period closed after gathering feedback from stakeholders across the healthcare sector. |
| February-April 2026 | More than 1,000 responses received from patients, healthcare organizations, industry representatives, and stakeholders. |
| 21 October 2026 | UK Government officially confirmed indefinite recognition of CE-marked medical devices and IVDs in Great Britain. |
| June 2030 | Current deadlines until legislation are made. |
| Ongoing | UKCA marking remains the domestic approval pathway while regulatory modernization initiatives continue. |
What Manufacturers Must Continue to Do
Although the announcement provides greater certainty, manufacturers should not assume that CE marking alone satisfies every requirement for placing a device on the GB market.
Organisations should continue to review the following compliance areas:
Manufacturers should also assess the applicability of any device-specific or transitional provisions rather than assuming that every CE-marked product automatically qualifies for indefinite recognition.
The Future of UKCA
The UK Government's decision to indefinitely recognize CE-marked medical devices in Great Britain has sparked industry-wide debate about the future of UKCA. While many manufacturers may now prefer a single CE certification route to access both the EU and GB markets, it would be early to say that UKCA is becoming obsolete. The demand for UKCA certification could decline but it is expected to remain important because it:
UKCA is unlikely to disappear, but it may shift from a mainstream certification route to a strategic regulatory tool.
Conclusion
The UK's decision to indefinitely recognize CE-marked medical devices represent one of the most significant regulatory developments for the medical device sector.
For manufacturers, the announcement reduces regulatory complexity, minimizes duplication, and provides long-term certainty regarding market access. For patients it will help in safeguarding access to innovative medical technologies.
While the UKCA pathway remains an important component of the domestic regulatory framework, the continued recognition of CE-marked devices demonstrates the UK's commitment to maintaining a globally connected, innovation-friendly, and patient-focused regulatory environment. As further reforms emerge, manufacturers should continue monitoring developments to ensure ongoing compliance within the Great Britain market.
Sushvin Consultancy Services continues to support medical device manufacturers in navigating evolving UK, EU, and global regulatory requirements, ensuring compliant and efficient market access strategies in an increasingly dynamic regulatory landscape.
Reference
Is Your Device Ready for the Great Britain Market?
CE marking may now be recognised indefinitely, but MHRA registration,UK Responsible Person duties, vigilance reporting and labelling rules still apply. Sushvin Consultancy Services can help you check where your products stand. Book a GB Market Access Review
Explore Sushvin’s Regulatory Services
Contact Sushvin For Best Quality and Regulatory Services for Medical Devices & Pharmaceutical Industries in UK, Europe
Stay informed with the latest insights, updates, and expert tips - subscribe to our monthly newsletter today!
Email us at info@sushvin.com | Medical Device Regulatory Updates - Monthly Newsletter | SUSHVIN Consultancy
